. Unité-de-pharmacovigilance, Commission nationale de pharmacovigilance. Compte-rendu de la réunion du mardi 25 mars, 2008.

B. Gay, F. Haramburu, and J. Gachie, Suivi biologique du traitement par AVK. http://agmed.sante.gouv .fr/pdf, etuavk.pdf, issue.18, pp.76-93, 2003.

J. Imbs, P. Pouyanne, F. Haramburu, M. Welsch, N. Decker et al., Iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance, Therapie, vol.54, issue.1, pp.21-28, 1999.

P. Pouyanne, F. Haramburu, J. Imbs, and B. Begaud, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000.
DOI : 10.1136/bmj.320.7241.1036

). Crpv and . Les, Hémorragies du système nerveux central associées à un traitement AVK : analyse des facteurs de risque Enquete menée avec les services de neurochirurgie français, etude I.htm. (24) CRPV de Bordeaux. EMIR: effets indésirables des Médicaments: Incidence et Risque, sur les hospitalisations liées à un effet indésirable médicamenteux, 2004.

E. De-maistre and T. Lecompte, Effets ind??sirables des traitements anticoagulants en dehors des h??morragies, Annales de Cardiologie et d'Ang??iologie, vol.51, issue.3, pp.1-5, 2002.
DOI : 10.1016/S0003-3928(02)00093-8

J. Hirsch, J. Dalen, D. Deykin, L. Poiler, and H. Bussey, Oral Anticoagulants, Chest, vol.108, issue.4, pp.231-277, 1995.
DOI : 10.1378/chest.108.4_Supplement.231S

). Has and K. Vitamine, Avis de la commission de Transparence. Haute Autorité de Santé, 2005.

T. Hanslik and J. Prinseau, The Use ???of Vitamin K in Patients on Anticoagulant Therapy, American Journal of Cardiovascular Drugs, vol.172, issue.12, pp.43-55, 2004.
DOI : 10.2165/00129784-200404010-00005

). Afssaps and . Ppsb, Résumé des caractéristiques du produit, 2006.

). Afssaps and K. Schéma-commun-des-antivitamine, http://afssaps.sante.fr/. (34) AFSSAPS. Transfusion de plasma frais congelé: produits, indications, 2000.

E. Hylek, Y. Chang, S. Skates, R. Hughes, and D. Singer, Prospective Study of the Outcomes of Ambulatory Patients With Excessive Warfarin Anticoagulation, Archives of Internal Medicine, vol.160, issue.11, pp.1612-1619, 2000.
DOI : 10.1001/archinte.160.11.1612

W. Ageno, D. Garcia, M. Silingardi, M. Galli, and M. Crowther, A Randomized Trial Comparing 1 mg of Oral Vitamin K With No Treatment in the Management of Warfarin-Associated Coagulopathy in Patients With Mechanical Heart Valves, Journal of the American College of Cardiology, vol.46, issue.4, pp.732-735, 2005.
DOI : 10.1016/j.jacc.2005.05.022

. ]. Lefrere and R. Girot, Acute cardiovascular collapse during intravenous vitamin KI injection (Ietter), Thromb Haemost, vol.58, p.790, 1987.

K. Songy and A. Layon, Vitamin K-induced cardiovascular collapse, Journal of Clinical Anesthesia, vol.9, issue.6, pp.514-523, 1997.
DOI : 10.1016/S0952-8180(97)00112-8

P. Barash, L. Kitahata, and S. Mandel, Acute cardiovascular collapse after intravenous phytonadione, Anesth Analg, vol.55, issue.43, pp.304-310, 1976.

. De-la-rubia, E. Grau, and A. Paya, Anaphylactic Shock and Vitamin K_1, Annals of Internal Medicine, vol.110, issue.11, p.943, 1989.
DOI : 10.7326/0003-4819-110-11-943_1

M. Martinez-abad and F. Delgado, Vitamine KI and anaphylactic shock (letter), Ann Pharmacother, vol.25, pp.871-873, 1991.

C. Wjasow and R. Mcnamara, Anaphylaxis after low dose intravenous vitamin K, The Journal of Emergency Medicine, vol.24, issue.2, pp.169-172, 2003.
DOI : 10.1016/S0736-4679(02)00720-5

A. Lubetsky, H. Yonath, and D. Olchovsky, Comparison of Oral vs Intravenous Phytonadione (Vitamin K1) in Patients With Excessive Anticoagulation, Archives of Internal Medicine, vol.163, issue.20, pp.2469-73, 2003.
DOI : 10.1001/archinte.163.20.2469

M. Crowther, J. Douketis, T. Schurr, L. Steidl, V. Mera et al., Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy, Annals of Internal Medicine, vol.137, issue.4, pp.251-255, 2002.
DOI : 10.7326/0003-4819-137-4-200208200-00009

M. Crowther, W. Ageno, and D. Garcia, Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin, Annals of Internal Medicine, vol.150, issue.5, pp.293-300, 2009.
DOI : 10.7326/0003-4819-150-5-200903030-00005

R. Weibert, D. Le, S. Kayser, and S. Rapaport, Correction of Excessive Anticoagulation with Low-Dose Oral Vitamin K_1, Annals of Internal Medicine, vol.126, issue.12, pp.959-62, 1997.
DOI : 10.7326/0003-4819-126-12-199706150-00005

J. Ansell, J. Hirsh, L. Poiler, H. Bussey, A. Jacobson et al., The Pharmacology and Management of the Vitamin K Antagonists, Chest, vol.126, issue.3, pp.204-233
DOI : 10.1378/chest.126.3_suppl.204S

R. Baker, P. Coughlin, A. Gallus, P. Harper, H. Salem et al., Warfarin reversaI: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis, Med J Aust, vol.181, issue.529, pp.492-499, 2004.

C. Landefeld, E. Cook, M. Flatley, M. Weisberg, and L. Goldman, Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy, The American Journal of Medicine, vol.82, issue.4, pp.703-716, 1987.
DOI : 10.1016/0002-9343(87)90004-0

S. Fihn, M. Mcdonell, D. Martin, J. Henikoff, D. Vennes et al., Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study, Annals of Internal Medicine, vol.118, issue.7, pp.511-531, 1993.
DOI : 10.7326/0003-4819-118-7-199304010-00005

V. Pengo, C. Legnani, F. Noventa, and G. Palareti, Oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study, Thromb Haemost, vol.85, issue.563, pp.418-440, 2001.

M. Reynolds, K. Fahrbach, . Hauch-0, G. Wygart, R. Estok et al., Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation, Chest, vol.126, issue.6, pp.1938-1983, 2004.
DOI : 10.1378/chest.126.6.1938

M. Fang, Y. Chang, E. Hylek, J. Rosand, S. Greenberg et al., Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation, Annals of Internal Medicine, vol.141, issue.10, pp.745-52, 2004.
DOI : 10.7326/0003-4819-141-10-200411160-00005

E. Hylek, A. Go, Y. Chang, N. Jensvo1d, L. Henault et al., Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation, New England Journal of Medicine, vol.349, issue.11, pp.1019-1045, 2003.
DOI : 10.1056/NEJMoa022913

S. Cannegieter, F. Rosendaal, and E. Briet, Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses, Circulation, vol.89, issue.2, pp.635-676, 1994.
DOI : 10.1161/01.CIR.89.2.635

G. Palareti, N. Leati, S. Coccheri, M. Poggi, C. Manotti et al., Bleeding complications of oral anticoagulation treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagu1ation (66) Audit of the frequency and c1inical response to excessive oral anticoagulation in and out-patient population, Am J Hematol, vol.59, issue.62, pp.22-29, 1998.

E. Hylek, H. Heiman, S. Skates, M. Sheehan, and D. Singer, Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation, JAMA, vol.279, issue.9, pp.657-62, 1998.
DOI : 10.1001/jama.279.9.657

J. Gurwitz, R. Goldberg, A. Holden, N. Knapic, and A. J. , Age-Related Risks of Long-term Oral Anticoagulant Therapy, Archives of Internal Medicine, vol.148, issue.8, pp.1733-1739, 1998.
DOI : 10.1001/archinte.1988.00380080037012

M. Gitter, T. Jeager, T. Petterson, B. Gersh, and M. Silverstein, Bleeding and Thromboembolism During Anticoagulant Therapy:A Population-Based Study in Rochester, Minnesota, Mayo Clinic Proceedings, vol.70, issue.8, pp.725-758, 1995.
DOI : 10.4065/70.8.725

F. Steffensen, K. Kritensen, E. Ejlersen, J. Dahlerup, and H. Sorensen, Major haemorrhagic complications during oral anticoagulant therapy in a Danish Population-based cohort, Journal of Internal Medicine, vol.305, issue.6, pp.497-503, 1997.
DOI : 10.1136/bmj.305.6867.1457

S. Fihn, C. Callahan, O. Martin, M. Donell, M. Henikoff et al., The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin, Annals of Internal Medicine, vol.124, issue.11, pp.970-979, 1996.
DOI : 10.7326/0003-4819-124-11-199606010-00004

M. Redwood, C. Taylor, B. Bain, and J. Matthews, The Association of Age with Dosage Requirement for Warfarin, Age and Ageing, vol.20, issue.3, pp.217-237, 1991.
DOI : 10.1093/ageing/20.3.217

J. Gurwitz, J. Avorn, D. Ross-degnan, I. Choodnovskiy, and A. J. , Aging and the Anticoagulant Response to Warfarin Therapy, Annals of Internal Medicine, vol.116, issue.11, pp.901-905, 1992.
DOI : 10.7326/0003-4819-116-11-901

K. Demirkan, M. Stephens, K. Newman, T. Self, J. Hirsh et al., Response to Warfarin and Other Oral Anticoagulants, Southern Medical Journal, vol.93, issue.5, pp.448-54, 1995.
DOI : 10.1097/00007611-200093050-00001

M. Debray, E. Pautas, P. Couturier, A. Franco, and V. Siguret, Mise au Point, M??dium, vol.43, issue.2, pp.107-117, 2003.
DOI : 10.3917/mediu.043.0006

S. Film, M. Donell, M. Martin, D. Henikoff, J. Vermes et al., Risk factors for complications of chronic anticoagulation, a mu1ticenter study, Warfarin Optimized Outpatient Follow-up Study Group, Ann Intern Med, vol.118, issue.78, pp.511-531, 1993.

L. Bodin and M. Loriot, La pharmacocinétique: application aux anticoagulants oraux, STV, vol.15, issue.07, pp.357-63, 2003.

R. Beyth, L. Quinn, and C. Landefeld, Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin ??????Access the ???Journal Club??? discussion of this paper at http://www.elsevier.com/locate/ajmselect/, The American Journal of Medicine, vol.105, issue.2, pp.91-100, 1998.
DOI : 10.1016/S0002-9343(98)00198-3

P. Wells, M. Forgie, and M. Simms, The Outpatient Bleeding Risk Index, Archives of Internal Medicine, vol.163, issue.8, pp.917-937, 2003.
DOI : 10.1001/archinte.163.8.917

S. Aspinall, B. Desanzo, and L. Trilli, Bleeding risk index in an anticoagulation clinic, Journal of General Internal Medicine, vol.288, issue.11, pp.1008-1021, 2005.
DOI : 10.1001/jama.288.19.2441

K. Dahri, P. Loewen, G. Evans, R. Luddington, and T. Baglin, The risk of bleeding with warfarin: A systematic review and performance analysis of c1inical prediction rules Beriplex PIN reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding, Thromb Haemost, vol.98, issue.8384, pp.980-987, 2007.

F. Preston, S. Laidlaw, B. Sampson, and S. Kitchen, Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients, British Journal of Haematology, vol.47, issue.3, pp.619-643, 2002.
DOI : 10.1111/j.1365-2141.1981.tb02764.x

A. Lubetsky, R. Hoffman, R. Zimlichman, A. Eldor, J. Zvi et al., Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversaI anticoagulation

M. Yasaka, T. Sakata, and H. Naritomi, Optimal dose of prothrombin complex concentrate for acute reversaI of oral anticoagulation Ultra-rapid management of oral anticoagulation therapy-induced surgi cal intracranial hemorrhage, Thromb Res Intensive Care Med, vol.115, issue.334, pp.455-464, 2005.

K. Frediksson, B. Norrving, and L. Stromblad, Emergency reversal of anticoagulation after intracerebral hemorrhage, Stroke, vol.23, issue.7, pp.972-979, 1992.
DOI : 10.1161/01.STR.23.7.972

M. Cartmill, G. Dolan, J. Byrne, P. Byrne, M. Lankiewicz et al., Prothrombin complex concentrate for oral anticoagulation reversaI in neurosurgical emergencies Urgent reversaI of warfarin with prothrombin complex concentrate (92) Sie P. How to we manage the hemorrhagic risk on hypovitaminosis K and treatmants with antivitamin K? Ann Fr Anesth Reanim1998, Br J Neurosurg J Thromb Haemost, vol.144, issue.17, pp.458-61, 2000.

S. Lee, E. Manno, and K. Layton, Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP, Neurology, vol.67, issue.7, pp.1272-1276, 2006.
DOI : 10.1212/01.wnl.0000238104.75563.2f

N. Boulis, M. Bobek, and A. Schmaier, Use of Factor IX Complex in Warfarin-related Intracranial Hemorrhage, Neurosurgery, vol.16, issue.5, pp.1113-1121, 1999.
DOI : 10.1002/ana.410160505

J. Lin, W. Hanigan, M. Tarantino, and W. J. , The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings, Journal of Neurosurgery, vol.107, issue.4, pp.737-777, 2003.
DOI : 10.1002/ana.410160505

W. Dager, J. King, R. Regalia, D. Williamson, R. Gosselin et al., Reversal of Elevated International Normalized Ratios and Bleeding with Low-Dose Recombinant Activated Factor VII in Patients Receiving Warfarin, Pharmacotherapy, vol.137, issue.8, pp.1091-1099, 2006.
DOI : 10.1001/jama.295.3.293

G. Dickneite, Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation, Thrombosis Research, vol.119, issue.5, pp.643-51, 2007.
DOI : 10.1016/j.thromres.2006.05.011

R. Beyth, L. Quinn, and C. Landefeld, A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized

T. Khan, F. Kamali, P. Kesteven, P. Avery, and W. H. , The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation, British Journal of Haematology, vol.26, issue.4, pp.557-64, 2004.
DOI : 10.1016/S0002-9343(98)00389-1

G. Afssaps-helft and J. Blacher, Automesure de l???INR??: pour quels patients???, La Presse M??dicale, vol.37, issue.6, pp.1069-1072, 2008.
DOI : 10.1016/j.lpm.2008.02.010

. Mesurer-l-', INR 7 à 10 jours avant l'intervention ? Si l'INR est en zone thérapeutique , arrêt des AVK 4 à 5 jours avant l'intervention et introduction des héparines à dose curative: -48 h après la dernière prise de fluindione (Previscan

@. Si-l, INR n'est pas en zone thérapeutique, l'avis de l'équipe médico -chirurgicale doit être pris pour